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ABSTRACT
Objectives: Ovale malaria is caused by two closely
related species of protozoan parasite: Plasmodium
ovale curtisi and Plasmodium ovale wallikeri
Although clearly distinct genetically, there have been
no studies comparing the morphology, life cycle or
epidemiology of these parasites. We tested the
hypothesis that the two species differ in the duration
of latency prior to presentation with symptoms of
blood-stage infection.
Design: PCR was used to identify P ovale curtisi
and P ovale wallikeri infections among archived
blood from UK malaria patients. Latency periods,
estimated as the time between entry into the UK and
diagnosis of malaria, were compared between the
two groups.
Setting: UK National Reference Laboratory.
Participants: None. Archived parasite material and
surveillance data for 74 P ovale curtisi and 60 P ovale
wallikeri infections were analysed. Additional
epidemiological data were taken from a database of
1045 imported cases.
Outcomes: None.
Results: No differences between the two species were
identified by a detailed comparison of parasite
morphology (N=9, N=8, respectively) and sex ratio
(N=5, N=4) in archived blood films. The geometric
mean latency period in P ovale wallikeri was 40.6 days
(95% CI 28.9 to 57.0), whereas that for P ovale curtisi
was more than twice as long at 85.7 days (95% CI
66.1 to 111.1; p=0.002). Further, the proportion of
ovale malaria sensu lato which occurred in patients
reporting chemoprophylaxis use was higher than for
Plasmodium falciparum (OR 7.56; p<0.0001) or
P vivax (OR 1.82; p<0.0001).
Conclusions: These findings provide the first
difference of epidemiological significance observed
between the two parasites which cause ovale malaria,
and suggest that control measures aimed at
P falciparum may not be adequate for reducing the
burden of malaria caused by P ovale curtisi and
P ovale wallikeri.
INTRODUCTION
Malaria is a mosquito-borne disease caused
in humans by six protozoan parasites
Plasmodium falciparum, Plasmodium vivax,
Plasmodium knowlesi, Plasmodium malariae,
Plasmodium ovale curtisi and Plasmodium ovale
wallikeri. The two latter species were only
recently differentiated, and are estimated to
cause more than 15 million African cases of
ovale malaria each year.1 P ovale curtisi and
P ovale wallikeri are thought to have diverged
from each other 1–2 million years ago, prob-
ably owing to the independent introductions
of proto-ovale parasites from primitive pri-
mates into the early hominid lineage.2 The
two species are found together across their
range in Africa and Asia, sometimes coinfect-
ing a single individual,1 3–7 providing compel-
ling evidence that true biological separation,
and not geographic isolation (allopatry), has
prevented genetic recombination between
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P ovale curtisi and P ovale wallikeri. However, to date, no dif-
ferences in morphology, life cycle, epidemiology or clin-
ical presentation in symptomatic patients have been
reported.
P ovale curtisi and P ovale wallikeri are both thought to
form latent hypnozoite stages in the liver, similar to
those of P vivax or the simian parasite Plasmodium cyno-
molgi.8 This has long been considered a general feature
of ovale malaria.9 Activation of hypnozoites may thus ini-
tiate blood-stage parasitaemia long after exposure to
biting mosquitoes; this can also lead to a secondary
febrile attack (relapse) some time after the chemothera-
peutic cure of a primary illness.10 Hypnozoites are
insensitive to almost all antimalarial drugs and therefore
can delay the onset of clinical malaria in people such as
travellers protected from a primary malaria episode by
temporary chemoprophylaxis; even in the absence of
antimalarials, hypnozoites of P vivax are implicated in
the observed delay in the occurrence of primary malaria
episodes in this species.11 This latency period can
present considerable difﬁculties for diagnosis of
imported malaria cases in non-endemic countries, as the
presenting symptoms appear to be unlinked to recent
foreign travel.12–14 It has been suggested that variation
in the duration of hypnozoite dormancy, and in the peri-
odic patterns of relapse, could lead to differences in the
measured latency period between P ovale curtisi and
P ovale wallikeri,1 but there are as yet no published data
which support this hypothesis. Further, a recent
appraisal of the relevant literature has led Richter et al15
to question the evidence for the existence of hypno-
zoites in ovale malaria at all. There is, therefore, a need
for further study of relapses in ovale malaria; one con-
venient approach is to compare the latency periods in
travellers infected with P ovale curtisi or P oval wallikeri,
and to evaluate the effect, if any, of chemoprophylaxis
in lengthening the observed latency.
We analysed cases of imported ovale malaria referred
to the Health Protection Agency Malaria Reference
Laboratory (HPA MRL) for which both the date of
arrival in the UK and date of diagnosis were available,
and for which an aliquot of the original blood sample
had been retained, permitting conﬁrmation of the
presence of P ovale curtisi or P ovale wallikeri in each case
by PCR. Parasite morphology data were collected by
re-examination of the original blood ﬁlms for a small
subset of samples; travel histories, demographic data and
records of chemoprophylaxis use were sourced from the
MRL malaria surveillance database. The duration of
latency was estimated for each case, and this was com-
pared between the two species groups.
METHODS
Collection of data and samples
The UK HPA MRL maintains an electronic database of
cases of malaria that have occurred in the UK since
198716; ad hoc recapture analysis suggests that
approximately 56% of imported malaria cases are repre-
sented in the database.17 This surveillance function is
based on passive case reporting by clinicians using data
collection methodologies that have not changed over
the last 20 years,18 although since 2005 all service users
sending blood ﬁlms for examination are requested to
also send an aliquot of the diagnostic blood sample to
the MRL for PCR investigations.19 We identiﬁed cases of
ovale malaria notiﬁed to the MRL between January 2003
and August 2011 with sufﬁcient data to estimate the
latency period prior to diagnosis, and for which a blood
sample had been provided for DNA extraction.
Ethics statement
This work was undertaken as part of the surveillance
activity of the MRL, as previously described.18 All
patient-identiﬁers were removed from the data prior to
extraction from the HPA MRL database. No additional
blood samples were taken from patients, other than
those required for the primary diagnosis of malaria.
Microscopic diagnosis
The parasite species present in all isolates were identi-
ﬁed by examination of Field’s-stained thick smears
and Giemsa-stained thin smears under oil immersion at
500–1000× magniﬁcation. Where the morphology was
not conclusive, species designations were conﬁrmed by
PCR as described below. Male gametocytes of P ovale
spp. were distinguished from female gametocytes by the
presence of a larger nucleus and more scattered haemo-
zoin (dark pigment).
Plasmodium species identification by PCR
Genomic DNA was extracted from blood samples using
the Qiagen blood mini kit (Qiagen, UK), according to
the manufacturer’s instructions. Parasite species were dis-
tinguished by PCR ampliﬁcation of small subunit riboso-
mal RNA genes, using minor modiﬁcations of methods
published elsewhere,20–22 to ensure ampliﬁcation, but
not discrimination, of both P ovale curtisi and P ovale walli-
keri.3 7 Discrimination of P ovale curtisi from P ovale walli-
keri was carried out by conventional ampliﬁcation of the
potra locus and quantitative real-time PCR (qPCR) ampli-
ﬁcation of the porbp2 locus, as previously described.3
Statistical analysis
The latency period, in days, for each episode of malaria
was calculated by subtracting the date of return from
travel (the last possible point in time when parasites
could have been introduced by an infectious Anopheles
bite) from the date of diagnosis in the UK.
Continuous variables were compared between species
using geometric means, and statistical signiﬁcance was
evaluated by the Wilcoxon rank-sum test. Associations
between pairs of binary variables were investigated in
2×2 contingency tables, and statistical signiﬁcance was
tested using the χ2 distribution, with Fisher’s exact cor-
rection when the expected frequency in any cell was
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5 or less. All statistical analyses were performed in
STATA v.12 (Timberlake, College Station, Texas, USA).
RESULTS
Seven hundred and ﬁfty-seven cases of malaria caused
by P ovale spp. were reported to the HPA MRL from
November 2003 (when EDTA-blood sample archiving in
the MRL was started) until the end of August 2011, for
which 573 (75.7%) blood samples, originally submitted
to the laboratory for primary or conﬁrmatory diagnosis,
were available for this study. Among these, we identiﬁed
134 samples for which sufﬁcient details of travel history
were available to estimate the latency period.
Species discrimination at the potra and porbp2 loci for
all 134 isolates identiﬁed 74 (55.2%) as P ovale curtisi
and 60 (44.78%) as P ovale wallikeri. Species assignments
by the two methods were in complete agreement for
each isolate. No mixed infections were identiﬁed in
which both species were present.
Parasite morphology and sex ratio
A small sample of 17 Povale spp. infections from 2011
and 2012, including two isolates from the 134 in the
main analysis, were selected on the basis that good-
quality blood ﬁlms (both thick and thin smears)
showing multiple life cycle stages were available, with an
estimated parasitaemia of at least 5 parasitised cells per
10 000 erythrocytes (0.05%; range 0.05–1.2%). These
comprised nine P ovale curtisi and eight P ovale wallikeri
infections. A single microscopist, blinded to the species
designations, collected descriptive data on each, includ-
ing the number of merozoites in each schizont-stage
parasite, the proportion of enlarged cells and the
arrangement and appearance of pigment (haemozoin)
depositions in the parasite cytoplasm. These data were
checked and conﬁrmed by another team member
before unblinding. None of the morphological para-
meters differed signiﬁcantly between the two species in
this small sample (data not shown). The sex ratio (pro-
portion of all gametocytes that were male) was deter-
mined for nine isolates in which at least 20 gametocytes
(range 24–117) were identiﬁed. The observed sex ratio
for both species was similar: for P ovale curtisi, the geo-
metric mean sex ratio was 0.33; 95% CI 0.26 to 0.40
(N=5) and for P ovale wallikeri, the sex ratio was 0.27,
95% CI 0.19 to 0.39 (N=4; p=0.32).
Patients, travel histories and prophylaxis use
Assuming that each infection was acquired during the
most recently reported journey, patients contracted
ovale malaria in at least 15 African countries, with
Nigeria and Ghana being the most commonly identiﬁed
places of origin, reﬂecting the popularity of these desti-
nations in travellers returning to or visiting the UK
(table 1). Stratifying the samples by geographic origin as
103 from West Africa (including Cameroon) and 28
from East/Southern Africa (including the Congo), no
difference was found in the proportion of the two
species in these two strata: P ovale curtisi comprised
53.4% and 57.1%, respectively (p=0.72). The three
remaining isolates were lacking information on speciﬁc
destinations within Africa.
Age, gender, prophylaxis use and duration of travel of
the study sample, stratiﬁed by parasite species, are pre-
sented in table 2. There were no signiﬁcant associations
between parasite species and the age (p=0.16) or sex
(p=0.509) of the patient, nor with the reported duration
of travel (p=0.42).
Although the MRL does not systematically collect data
on the use of mosquito protection measures such as
repellents or bednets, information on malaria chemo-
prophylaxis use is collected and was available for 112
patients. Overall, 37 (33%) patients with ovale malaria
reported the use of some form of chemoprophylaxis
(table 2), but this did not signiﬁcantly affect which
species of parasite was present: of those infected with P
ovale curtisi, 21 used prophylaxis, whereas of those
infected with P ovale wallikeri, 16 used prophylaxis
(p=0.46). Among the different drugs used for prophy-
laxis, atovaquone-proguanil was more often used by
those who later presented with an infection of P ovale
wallikeri, but this was not statistically signiﬁcant (OR 3.6,
95% CI 0.59 to 26.3; Fisher’s exact p=0.14).
To compare these data with the effect of prophylaxis
use on other Plasmodium species, both non-relapsing
and relapsing, we extracted information on prophylaxis
use among UK malaria patients between 1991 and 2010,
including a sample (evenly spread across the time
period) of those presenting with P falciparum (N=2814;
7.5% reported at least some prophylaxis use) and all
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available data for P vivax (N=4,133; 23.7% used prophy-
laxis). These data were compared with all available data
for P ovale spp. (N=1,045; 36.2% used prophylaxis).
Thus, the proportion of malaria cases caused by P ovale
spp., which occurred among people reporting prophy-
laxis use, was higher than the corresponding ﬁgure for
P falciparum (OR 7.56; 95% CI 6.23 to 9.17; p<0.0001),
and also signiﬁcantly higher than the ﬁgure for the
known relapsing parasite P vivax (OR 1.82; 95% CI 1.57
to 2.11; p<0.0001). However, this latter comparison may
be affected by the fact that chemoprophylaxis is less fre-
quently recommended for travellers to Pakistan and
India, from where the majority of cases of vivax malaria
originated, than for Africa, the origin of virtually all
ovale malaria cases in the UK.
Latency analysis
The geometric mean latency period for P ovale curtisi
infections was 85.7 days (95% CI 66.1 to 111.1) and for
P ovale wallikeri infections was 40.6 days (95% CI 28.9 to
57.0; ﬁgure 1), giving a geometric mean difference in
latency period for these species of 45.1 days (Wilcoxon
rank-sum: z=3.087; p=0.0020). These compare with an
estimated geometric mean latency for P vivax, from the
MRL database, of 57.2 days (95% CI 54.8 to 59.8 days;
N=4,920). For each of these relapsing species, no
attempt was made in the analysis to distinguish primary
infections from relapse infections—all cases of each
species with sufﬁcient data were analysed together. One
P ovale curtisi infection displayed an extraordinary
latency period of 1083 days; removal of this outlier only
slightly reduced the estimate of the geometric mean
latency period for this species to 82.7 days (95% CI 64.2
to 106.6), and the interspecies difference remained sig-
niﬁcant (Wilcoxon rank-sum: z=2.984; p=0.0028).
Information on prophylaxis use was available for 112
cases, of whom 37 reported taking at least some chemo-
prophylaxis. Of the 58 evaluable cases with P ovale curtisi
infection, geometric mean latency was 88.6 days (95%
CI 59.0 to 132.8) among the 37 who reported taking no
prophylaxis, compared with 69.9 days (95% CI 45.2 to
108.2) among the 21 reporting at least some prophylaxis
use (p=0.544). Of the 54 evaluable cases with P ovale
wallikeri, geometric mean latency was 33.9 days (95% CI
21.9 to 52.6) among the 38 who did not report prophy-
laxis use. However, the corresponding geometric mean
latency was almost twice as long among the 16 using
prophylaxis at 60.4 days (95% CI 33.7 to 108.1; p=0.179),
suggesting a weak, non-signiﬁcant impact of chemo-
prophylaxis on the latency period of P ovale wallikeri.
DISCUSSION
Latency periods differ for P ovale curtisi and P ovale
wallikeri
In this descriptive study, the human malaria parasites
P ovale curtisi and P ovale wallikeri are shown to differ
Figure 1 Latency in days of Plasmodium ovale spp.
infections in 134 UK travellers. The geometric mean number
of days elapsing between arrival in the UK and diagnosis of
ovale malaria is given for all patients. The midline of each
box-plot is the median, with the edges of the box representing
the interquartile interval. Whiskers delineate the 5th and
95th percentiles.
Table 2 Characteristics of the study population




(31.7 to 37.9; 12–71)
31.5
(27.9 to 35.1; 2–62)
Gender
Females, N (proportion) 21 (28.4%) 14 (23.3%)
Prophylaxis use*




Duration of travel (days)*
Geometric mean (95% CI)
N
43.1 (30.6 to 60.7)
39
52.6 (37.3 to 74.0)
36
*Data were incomplete for these categories.
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signiﬁcantly in the latency period in travellers with ovale
malaria diagnosed in the UK. Despite substantial and
compelling genetic divergence between the two
species,1 3 no differences have hitherto been found in
morphology, geographic distribution, epidemiology or
clinical features of disease. The current analysis thus pro-
vides the ﬁrst evidence that malaria infections caused by
these two similar but genetically distinct species differ in
a clinically important feature. Our data also suggest that
ovale malaria, caused by either P ovale curtisi or P ovale
wallikeri, is less likely to be prevented by chemoprophy-
laxis than are the other forms of human malaria. Thus,
these two species together present particular challenges
to malaria control and eradication programmes.
Long latency periods and the delayed onset of symp-
tomatic malaria present considerable difﬁculties for
disease diagnosis and the swift provision of appropriate
treatment.13 Delayed diagnosis can worsen clinical out-
comes and increase morbidity,23 thus increasing the
costs to healthcare systems. Our assessment of latency
periods in imported cases of ovale and vivax malaria
demonstrates that delayed onset malaria must remain a
differential diagnosis of fever when any history of travel
to malaria-endemic countries is months, or even years,
in the past. The longest recorded period of latency in
our dataset was 1083 days, in a case of P ovale curtisi
infection.
P. ovale spp. and relapse malaria
Richter et al15 have argued that insufﬁcient evidence is
available to unequivocably demonstrate that P ovale spp.
are able to form ‘true’ hypnozoites which subsequently
cause relapse malaria. Although lack of biological evi-
dence from ex vivo liver-stage studies is indeed a
problem, the data presented here would support the
presence of ovale hypnozoites in two ways. First, a rela-
tively high proportion (36.2%) of imported cases of
ovale malaria are in people who report the use of
prophylaxis, being much higher than the proportion in
those who contracted falciparum malaria (6.4%) and
slightly higher than for vivax malaria (23.7%), a known
relapsing malaria species with well-described hypno-
zoites. Second, the observed latency periods for the two
ovale malaria species, at 85.7 and 40.6 days, respectively,
are similar to those for vivax malaria cases (57.2 days).
These ﬁndings are consistent with both P ovale curtisi
and P ovale wallikeri being true relapse malaria species,
and indirectly infer the presence of hypnozoites in both
species. Further biological studies of P ovale spp.,
perhaps in cultured liver cells, are required to provide a
further understanding of latency in ovale malaria.
Species differentiation/morphology of P ovale curtisi
and P ovale wallikeri
Our morphological observations did not identify any
feature that could discriminate between P ovale curtisi
and P ovale wallikeri, but continuing careful descriptive
microscopy of these two parasites may eventually ﬁnd
such a criterion. We present here the ﬁrst attempt to
compare the sex ratio of the two species; although no
difference was found in this small sample, the estimated
sex ratio of approximately 0.3 (ie, just over 2 male game-
tocytes to every female gametocyte in peripheral blood
smears) is quite different from the estimate of 0.13 (ie,
eight males for every female gametocyte) observed with
cultured P falciparum.24 Further work is required to
conﬁrm this estimate, and studies of gamete emergence
(ex-ﬂagellation) in ex vivo preparations of the gameto-
cytes of P ovale spp. may also shed further light on the
true sex ratio.
Study limitations
There are several limitations to our study. First, as a ref-
erence level laboratory receiving parasite-infected blood
from a wide variety of source facilities across the UK, the
available material does not come as the result of care-
fully planned sampling strategies, but simply reﬂects the
most common malaria-endemic destinations for UK tra-
vellers; the most common countries of origin of African
migrants to the UK; and laboratory referral patterns.
Although this does include West Africa and East/
Southern Africa, all of Asia and many countries in Africa
are missing from our sample set. For example, French
workers have recently described 90 imported ovale
malaria cases of both species from the Ivory Coast and
the Comoros Islands,6 locations contributing only three
individuals in our sample set (table 1). Second, in the
absence of an exact date of infection, our measure of
latency uses the date of arrival in the UK as a proxy.
This is an obvious source of imprecision, but means that
in every case the latency period used in the analysis is a
minimum estimate. Further, this imprecision is expected
to be of approximately equal magnitude, on average, for
infections with P ovale curtisi as for those with P ovale wall-
ikeri. Therefore, there is no a priori reason to consider
this as a source of confounding. Third, we do not cur-
rently have the tools to distinguish primary ovale malaria
attacks, being the ﬁrst blood stage parasite expansion
since mosquito inoculation, from relapse malaria caused
by the activation of previously dormant hypnozoites; in
some cases, these may have been present for years.
Therefore, our latency data for each species may mask
two distinct natural histories; future studies with larger
datasets could beneﬁt from model-ﬁtting to explore this
aspect in more detail. Finally, the data used to deter-
mine prior prophylaxis use is notoriously unreliable:
patients may have taken incomplete or sporadic courses
which did not provide sufﬁcient chemo-protection.25
Nevertheless, these data will be equally ﬂawed across all
the species used for the comparative analysis, and thus
the broad differences we observed are likely to be bio-
logically real. Interestingly, there is a hint in our data
that prophylaxis affects the latency period in P ovale wall-
ikeri infections more than in P ovale curtisi infections.
Further studies, deploying more detailed patient histor-
ies, are needed to investigate this further.
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Recommendations
Delayed onset malaria is responsible for a small but
important subset of imported malaria cases in the UK,
and P. ovale spp. parasites are disproportionate contribu-
tors to this. Longitudinal studies in endemic countries
are needed to investigate the mechanisms of these
apparent prophylaxis breakthroughs. P ovale curtisi and
P ovale wallikeri differ in latency patterns; further studies
of the clinical and epidemiological features of these two
parasites may identify other differences.
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